Chimeric Therapeutics - Acquiring a promising first-in-class CAR T asset
Chimeric recently announced that it will be licensing a chimeric antigen receptor t-cell (CAR T) programme targeting cadherin 17 (CDH17) from the University of Pennsylvania. Specific financial terms are undisclosed, but they include an upfront fee, annual maintenance fees, milestones and a royalty (likely single digit, in our view). A CDH17 CAR T may have broad applicability in solid tumours, particularly in neuroendocrine, colorectal, pancreatic and gastric cancers. Importantly, preclinical evidence suggests the therapy may be able to eradicate tumours with little to no toxicity to normal tissues. The CDH17 CAR T is expected to enter the clinic in 2022.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.